What It Means to Be A Libertarian HD
What does it mean to be a libertarian? Dr. Jeffrey Miron at Harvard offers one answer. According to Miron, libertarians have enormous respect for individual decisions. While other ideologies attempt to use government force to advance their ideas of how people should act or behave, libertarians think that individuals should be able to live their own lives as they see fit. From LearnLiberty.org.
By: ButISay
See the original post:
Improving Libertarian Arguments (a Critique of Anti-Government Talking Points)
A Video By Alex Merced Support Alex Merced donate.alexmerced.com AlexMerced.com - LearnEconomicsNow.com - Libertarian101.com
By: Alex Merced
The rest is here:
Improving Libertarian Arguments (a Critique of Anti-Government Talking Points) - Video
MineThis1 Quotes to Austrian Libertarian Peter Schiff Bots Pt 1
Food for thought. Enjoy! 🙂
By: Minethis1
Visit link:
MineThis1 Quotes to Austrian Libertarian Peter Schiff Bots Pt 1 - Video
Austrian, Libertarian, Peter Schiff Bot Initiation Video.
This fucker was right it all along! He was talking about the financial crisis, founding fathers, liberty, boom and busts and the coming apocalypse way before Schiffy! WOW!!! 🙂
By: Minethis1
Read more:
Austrian, Libertarian, Peter Schiff Bot Initiation Video. - Video
DbZ: Why People Don #39;t Listen to "Libertarians"
Though I don #39;t agree with libertarian thought and policy, I am open to debate and dialogue. However, libertarians need to be aware that there are a few things standing between them and discourse. Some of it is their doing, some of it is a matter of presentation. In the spirit of getting some discussion going, a few observations from someone on the left end of the spectrum. Main Site: randomology.org Charcoal Streets Previews randomology.org Facebook: http://www.facebook.com Twitter Feed: twitter.com
By: dagger3001
Continue reading here:
waka islands Part 1! (minecraft)
this is WAKA ISLAND my sister is the crapyest cameraman ever sorry i could barly hear me
By: Haloslast Hope
See the original post here:
Channel Islands Biscuit Review
Im reviewing my brand new al merrick biscuit 5 #39;8, i got it at red dog surf shop in new smyrna beach Florida and i got a boardbag,stompad,leash deal for 75$
By: rad24b
Read the rest here:
Cliff Diving | Hundred Islands Pangasinan
By: Patti Manalang
Original post:
THE DETWILERS TAKE THE CAYMAN ISLANDS
Our trip to Cayman Islands in 3 minutes or less
By: ginabina61
Go here to see the original:
Cruising off the Toronto Islands
Early summer morning sail on Lake Ontario.
By: alaw1044
Link:
The Rainbow Warrior is heading to the Auckland Islands which is home to critically endangered sea lions, yellow eyed penguins and Gibsons albatross. The islands and surrounding marine reserve are listed as a World Heritage Area, alongside the Egyptian Pyramids and the Grand Canyon.
Following the departure from Lyttleton yesterday, the Rainbow Warrior is currently sailing through the oil drilling zone off Canterbury that Anadarko plans to drill in by the end of 2013. Here the Rainbow Warrior crew saw juvenile sperm whales feeding on the surface surrounded by royal albatross, giant petrels and a number of other sea birds who call this area home.
"The Government wants to open up vast areas for deep sea oil drilling south of Dunedin, Stewart Island, and into the wild seas towards the Auckland Islands. Many of our incredible and rare native birds, sea lions and whales live here and would be at risk," said Bunny McDiarmid, Executive Director of Greenpeace New Zealand.
The Rainbow Warrior is expected to arrive at the Auckland Islands on Thursday 31 January and depart Sunday 3 February after documenting some of our most marvellous wildlife. On Monday 4 February they will be documenting the wildlife of Snares Island, south of Stewart Island.
In December the Government also gave out new deep sea oil and gas exploration permits:
- Out from Dunedin to Shell, OMV and Mitsui in the Great South Basin
- Out from Wellington/Wairarapa/Marlborough to Anadarko which also puts Kaikoura in the the spill zone
Read more:
Free health clinics around the Kansas City area, like many across the country, are shedding their free designation and preparing to accept payment from most patients as they adapt to the federal health care law.
The shift will be a big one, especially for the bustling Kansas City Free Health Clinic in midtown. Its one of the largest free clinics in the country, treating upward of 15,000 patients a year with more than 100 staff members and 1,000 volunteers.
In its 42 years, KC Free, as its commonly called, hasnt charged fees or billed patients for care. And it has seen only the uninsured.
Soon, all that will change.
Like several other free clinics across the country, KC Free will soon accept Medicaid and add a sliding fee scale. The dramatic shift in the non-profits business model is necessary under the new law, its leaders say, and will allow the clinic to continue caring for many of Kansas Citys most vulnerable residents.
The face of health care is changing, and we are changing with it. We must, Sheri Wood, the clinics executive director, wrote in a letter to volunteers and supporters in December.
Similarly, the Health Partnership Clinic of Johnson County has shifted its structure; and the Duquesne Clinic in Kansas City, Kan., has changed the definition of whom it serves and may start accepting Medicaid. Other health care providers are moving away from an urgent care approach in an effort to become a primary medical home for patients. Community mental health centers have started offering medical services to some patients, too.
With federal law aiming to expand health coverage, the entire safety net is realigning in preparation for an influx of patients accessing care for the ry first time, or for the first time in a very long time. And yet, parts of the law itself are still unclear, and much of how everything unfolds locally depends on how Missouri and Kansas implement the law.
We are entering a new era, and I think that free clinics are very consciously trying to decide what the best path is, said Julie Darnell, professor of Health Policy at the University of Illinois-Chicago.
A clinic for hippies
See the article here:
Sen. Shannon Jones said she is impressed with recent development in the city during a meet and greet Monday at Cincinnati State Middletown.
The Clearcreek Twp. Republican, who represents Ohios 7th Senate District, will now represent constituents in the citys 4th Ward and parts of the 2nd Ward because of redistricting.
Middletown really has a lot going on, she said, citing the East End development and the rejuvenation of this downtown area.
Jones is entering her seventh year working in Columbus, first taking office in the Ohio House in January 2007.
She was appointed to her Senate seat in August 2009 following the death of the late Sen. Bob Schuler, and subsequently elected in November 2010. The district had included Warren Countys portion of Middletown. She talked exclusively with The Middletown Journal during her visit Monday.
Q: Middletowns 4th and 2nd wards are rather different from the suburban communities youve represented in the past. How can you help these two areas of the city?
A: I think the biggest thing I can do it to just be present and to listen to people, rather than me dictate to them what their needs are. Im here today to listen to whats on peoples minds.
Q: What do you hope to learn about the community?
A: I hope to learn what the core institutions are in the community because that gives me a sense of what the community values are, as well as the key people who are active in the community. Once you sort of know what the landscape looks like, I just plan to be around and listen and learn.
Q: It appears Middletown and the region are becoming an educational hub in addition to being a health care hub. Is this good for the region?
View post:
It's a good day for companies reporting earnings, and strong quarters are powering the Dow Jones Industrial Average (DJINDICES: ^DJI) higher. The Dow has rocketed to yet another 52-week high, continuing to surge through the start of 2013. As of 2:20 p.m. EST, the index has pulled in gains of 70 points, or 0.51%. Let's check out the biggest names making moves today.
A healthy dose of optimism It's a great day to be a health care investor, and Pfizer (NYSE: PFE) is leading the charge on the Dow. Along with several other companies, Pfizer reported earnings that smashed expectations. The company's profit almost quadrupled from a year ago, buoyed by its sale of its nutrition business to Nestle. Despite the patent loss of best-selling blockbuster Lipitor last year, Pfizer's earnings, even without the Nestle sale, slightly topped analyst projections. And despite the hit to Lipitor sales, revenue also beat the Street's best guess.
So far, Pfizer's shares have risen more than 3.2% to hit a new 52-week high.
The optimism around the medical industry has pushed Merck (NYSE: MRK) higher as well, even though the company doesn't report its quarterly data until later in the week. Merck is among the leaders of the Dow, up 1.5% so far today. The company is dealing with its own patent-loss blues, as declining sales of Singulair have weighed on growth expectations. Merck investors could use a good report; the stock has lost nearly 6% over the past three months.
Johnson & Johnson (NYSE: JNJ) and Unitedhealth Group have also swung up on the day, with shares gaining a little more than 1% each. J&J recently reported earnings that beat expectations, but its 2013 guidance disappointed Wall Street. The company is debating selling or spinning off its diagnostics business in its search for new growth. The guidance hit hasn't stopped this stock from hitting a new 52-week high as well, however.
Even outside the health care field, stocks on the Dow lean heavily toward winners. However, Hewlett-Packard (NYSE: HPQ) is leading the small corps of laggards down today, with shares falling 3.9%. Reports have surfaced from a PDF file on the company's website that HP may be preparing to launch its own version of Google's Chromebook, a laptop operating on Google's Chrome OS. However, with the PC market under fire, it'll take a lot more than that to turn this beleaguered company around.
Interested in Johnson & Johnson? Health care stocks are dominating the headlines today, and there's no bigger player in the sector than medical colossus Johnson & Johnson. Offering everything from baby powder to biologics, the company is considered by some to be spread too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand-new premium report on Johnson & Johnson. To claim your copy, simply click here now for instant access.
The rest is here:
SAN DIEGO, Jan. 29, 2013 /PRNewswire/ --Cardium Therapeutics (NYSE MKT: CXM) today announced a presentation at the 2013 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. The Company's presentation, "Optimizing Phase III Trial Design for Generx (Ad5FGF-4)" by Cardium's Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D. outlined the current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and discussed the lessons learned during the past decade of the Company's Generx clinical development program. The presentation is available for viewing at http://www.cardiumthx.com/generx.html.
(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)
"The presentation yesterday reviewed new techniques that have been implemented to optimize our international Phase 3 ASPIRE clinical study for the Company's Generx (Ad5FGF-4) DNA-based angiogenic growth factor drug candidate, including: (1) diagnostic identification of patients likely to be more responsive to angiogenic therapy; (2) new balloon catheter-based delivery methods designed to boost adenovector gene delivery and enhance angiogenic growth factor efficiency; and (3) selection of relevant clinical endpoints which may be useful in future clinical studies and help advance the field of therapeutic angiogenesis," stated Christopher J. Reinhard, Cardium's Chairman and CEO.
Generx is an interventional cardiology-focused product candidate that is being developed to offer a one-time, non-surgical option for the treatment of a medical condition termed cardiac microvascular insufficiency (CMI) in patients with myocardial ischemia and symptomatic chronic stable angina pectoris due to coronary artery disease. Patients with CMI have had an insufficient angiogenic response to their current disease state and may benefit from a biological therapy that enhances cardiac perfusion through the facilitation of collateral vessel formation. Currently, patient inclusion in the ASPIRE study requires evidence of stress induced reversible myocardial ischemia as measured by SPECT imaging. The goal of the Company's Generx product candidate is to improve blood flow to the heart muscle by promoting and enhancing cardiac perfusion through the enlargement of pre-existing collateral arterioles (arteriogenesis) and the formation of new capillary vessels (angiogenesis). Various catheter-based imaging diagnostics including fractional flow reserve and washout collaterometry could enhance the clinical adoption of this non-surgical therapeutic angiogenesis approach following initial registration.
Cardium's extensive preclinical and clinical studies have been instrumental in identifying cardiac ischemia as a key facilitator of non-surgical DNA-based angiogenic therapy. Improved adenovector administration methods combine non-surgical, percutaneous balloon catheter-based delivery to transiently induce ischemia together with the use of nitroglycerin to enhance vector uptake. By increasing cell transfection efficiency and reaching both the peri-ischemic regions and pre-existing collaterals in the heart, this modified approach offers the potential to effectively simulate both angiogenesis and arteriogenesis to bring about improved blood flow. Cardium's new delivery techniques are also designed to provide uniform Generx uptake, to reduce response variability and to allow for the potential treatment of patients with a broader range of associated coronary artery disease.
Cardium has modified the primary endpoint of the ASPIRE clinical study from the traditional measure of improvement in treadmill exercise time (ETT) to a more objective efficacy endpoint of reduction in reversible perfusion deficit based on SPECT myocardial perfusion imaging. Similar to mechanical/surgical cardiac revascularization approaches, the goal of Generx treatment is to improve myocardial perfusion (blood flow). SPECT myocardial perfusion imaging can be used to quantitatively evaluate Generx's effectiveness by measuring improved myocardial blood flow under stress, a key prognostic indicator that is associated with the regenerative process of new collateral vessel formation in and around the regions of ischemia. While walking time during ETT has been a traditional efficacy measure of anti-anginal drugs, it is based on a subjective assessment of chest pain (angina pectoris), does not directly measure improvements in cardiac blood flow, and can be affected by other variables. Positive results from the prior Phase 2a clinical study (Grines et al., J Am Coll Cardiol 2003; 42:1339-47) showed that Generx improved myocardial blood flow in the ischemic region of the hearts of patients following a single intracoronary infusion as measured by the objective efficacy endpoint of SPECT imaging. The observed treatment effect for patients receiving Generx was similar in magnitude to that reported in the literature for patients undergoing angioplasty/stent or revascularization procedures with reversible perfusion defects of comparable size at one year following these procedures.
ASPIRE Study
The ASPIRE study is a 100-patient, randomized and controlled multi-center study currently enrolling patients at up to eight leading cardiology centers in the Russian Federation. The ASPIRE study is designed to further evaluate the safety and effectiveness of Cardium's Generx DNA-based angiogenic product candidate, which has already been tested in clinical studies involving 650 patients at more than one hundred medical centers in the U.S., Europe and elsewhere. The efficacy of Generx is being quantitatively assessed using rest and stress SPECT (Single-Photon Emission Computed Tomography) myocardial imaging to measure improvements in microvascular cardiac perfusion following a one-time, non-surgical, catheter-based administration of Generx. The Cedars-Sinai Medical Center Nuclear Cardiology Core Laboratory in Los Angeles, California, is the central core lab for the study and is responsible for the analysis of SPECT myocardial imaging data electronically transmitted from the Russian medical centers participating in the ASPIRE study. The Russian Health Authority has assigned Generx the therapeutic drug trade name of Cardionovo for marketing and sales in Russia.
An independent long-term prospective study published in Circulation (Meier et al, Circ. 2007; 116:975-983) provided key evidence indicating that men and women with more recruitable collateral circulation have a better chance of surviving a heart attack than patients who have less developed collateral circulation. This important study quantitatively evaluated coronary collateral blood flow in 845 patients with coronary artery disease during a 10-year follow-up period and showed that long-term cardiac mortality was approximately 66% lower in patients with a well-developed coronary collateral network (p=0.019). For the first time, this study showed the importance of collateral circulation beyond simply the relief of angina and provided further support of the potential for long term benefits from angiogenic therapy.
About Cardium
Visit link:
Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum
Extreme Metaversal Futurist Manifesto 12-21-12
Johannes Ayres of Metaversal Lightcraft/Iaocore reads his Futurist Manifesto at a sunrise press conference on the rooftop of the fabulous Standard Hotel in downtown Los Angeles kicking off the Extreme Futurist Festival on December 21, 2012....
By: Johannes Ayres
Excerpt from:
A Futurist Scene - Student Reel 2009
A futurist scene for a student reel in 3D modelling and animation back in 2009. Rendered in Maya at PAL resolution hence the black side bars. Share your 3D models, reels and scenes with the community at 3DSquirrel.co.uk.
By: 3DSquirrels
Read the original post:
New Delhi, Jan 29 (IANS) "Democratisation" of the information sector, with easy access to news and social media platforms, should take into account implications on social ethics and norms, and freedom of speech should not extend to the right to offend, Information and Broadcasting Minister Manish Tewari said here Tuesday.
Addressing a function of the Broadcast Engineering Society, Tewari said media should take to self-regulation "as an instinct".
"With the democratization of the information paradigm, it has to take into account what are the implications on social ethics, social milieu, social norms... Freedom of speech should not extend to the right to offend", he continued, adding that a "remedy" should be found to the issue.
Referring to social media, Tewari said there is "need to make a distinction between right to privacy and the right to know".
"The right to anonymity can be corrosive to social order," he said.
The minister's comments can be seen in reference to many postings critical of the government by anonymous accounts as well as imposter accounts posing as the Prime Minister's Office or poking fun at the prime minister on the social media network Twitter.
The minister said the broadcasting space has seen a huge expansion in the past two decades, from one broadcaster in 1990 to over 850 television channels, while FM radio has also expanded in the past five years. The social media has also expanded with around seven crore users.
This posed a question "whether regulation has been able to keep pace with the march of technology," said Tewari.
"For orderly development of any sector, it is a prerequisite that enabling regulations of statutory architecture should keep pace with the changes as it unfolds," he added.
On TRPs and sensationalism in TV media, Tewari said the issue needs to be deliberated whether it is due to the "skewed revenue model or an addiction that people have got into".
See the rest here:
Freedom of speech must not extend to right to offend: Tewari
PeopleMatter Automates HR with Comprehensive Hire-to-Retire Solution
Charleston, SC (PRWEB) January 29, 2013
We were looking for a software package that could do more than applicant tracking, said Rick Cagle, Vice President and Director of Operations for Erickson Oil Products/Freedom Valu Centers. We wanted a system that offered training and scheduling, in addition to applicant tracking.
PeopleMatter provides Freedom Valu with a configurable, flexible and easy-to-use HR Platform that offers hiring, training and scheduling all from one online portal. Unlike many HR solutions in the market, PeopleMatter is designed specifically for the service industry and hourly workforce. All the Platforms tools and features are built to accommodate the unique needs of multi-unit operators a key request for companies like Freedom Valu.
With stores located in the metropolitan and suburban areas of Minnesota, Wisconsin, South Dakota and Michigan, Freedom Valu managers can easily share applications and employee schedules across locations. Additionally, if an employee moves from one state to another, managers can quickly transfer the employees file to the Freedom location closest to the employees new address. The software syncs all of the data and employees instantly throughout the system and keeps on-the-go teams up-to-date.
We have been very impressed with the speed and accuracy of moving our information into the system. The transition has been good from the beginning to deployment, said Rick Cagle, Vice President and Director of Operations Erickson Oil Products/Freedom Valu Centers. Traditionally implementations are laborious. But turning on PeopleMatter and using the system has been easy and flawless.
Using the integrated modules and components of the PeopleMatter Platform provides a lot of flexibility not found in point solutions. Capabilities include the:
By providing an integrated training and scheduling solution, PeopleMatter meets a need Freedom Valus previous point solution left unfulfilled. PeopleMatters comprehensive Platform works how today's workforce works via mobile smartphones, tablets, browsers and voice-activated devices.
Having clients move from a point solution to the PeopleMatter Platform is always a validation of our product, said Nate DaPore, PeopleMatter President and Chief Executive Officer. It is wonderful to see new clients like Freedom Valu Centers embrace our easy to-use tools that meets their needs and grows with the company.
About Freedom Valu Centers
Read the rest here:
Freedom Valu Selects PeopleMatter to do More Than Just Job Apps